Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0009 Transporter Info
Gene Name SLC22A3
Transporter Name Organic cation transporter 3
Gene ID
6581
UniProt ID
O75751
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Quinine

            4 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 18.3 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT3

  DT Modulation 2

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 37 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  DT Modulation 3

 Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 22.7 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  DT Modulation 4

 Quinine inhibits the activity of SLC22A3 [4]

  Clonidine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Clonidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 373 microM) [5]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human retinal pigment epithelial (HRPE) cells-OCT3

  DT Modulation 2

 Clonidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 110 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Desipramine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Desipramine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 14 microM) [5]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human retinal pigment epithelial (HRPE) cells-OCT3

  DT Modulation 2

 Desipramine inhibits the activity of SLC22A3 [7]

  Metformin

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Metformin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 2332 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT3

  DT Modulation 2

 Metformin inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 904 microM) [6]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Ranitidine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 290 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT3

  DT Modulation 2

 Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 372 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 2.88 microM) [8]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Phenoxybenzamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 6.13 microM) [8]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Progesterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 4.28 microM) [8]

Affected Drug/Substrate

 1-Methyl-4-phenylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Ergotidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ergotidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 140 microM) [9]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Imipramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Imipramine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 42 microM) [5]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human retinal pigment epithelial (HRPE) cells-OCT3

  Procainamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Procainamide inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 738 microM) [5]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human retinal pigment epithelial (HRPE) cells-OCT3

  Famotidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Famotidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 6.7 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT3

  Atropine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Atropine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 466 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Diphenhydramine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 695 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Amantadine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Amantadine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki > 1000 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Cocaine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cocaine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki > 1000 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Dextroamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 460 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Ketamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ketamine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 225.7 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Memantine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Memantine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 236 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Pentamidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 14.8 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Prazosin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Prazosin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 12.6 microM) [8]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Mifepristone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mifepristone inhibits the expression of SLC22A3 [12]

  Phenobarbital

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenobarbital affects the expression of SLC22A3 [13]

  Copper Sulfate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Copper Sulfate inhibits the expression of SLC22A3 [14]

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin inhibits the expression of SLC22A3 [15]

  Acetaminophen

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Acetaminophen inhibits the expression of SLC22A3 [16]

  Decitabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decitabine affects the expression of SLC22A3 [17]

  Hydrogen Peroxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Hydrogen Peroxide affects the expression of SLC22A3 [18]

  Menadione

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Menadione affects the expression of SLC22A3 [18]

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid affects the expression of SLC22A3 [19]

  Mdv-3100

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Mdv-3100 inhibits the expression of SLC22A3 [20]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Doxorubicin affects the expression of SLC22A3 [21]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine inhibits the expression of SLC22A3 [22]

Drug in Phase 3 Trial

  Corticosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Corticosterone inhibits the activity of SLC22A3 [8]

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan inhibits the expression of SLC22A3 [28]

Drug in Phase 2 Trial

  YM155

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 YM155 inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 108 microM) [11]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  MeIQx

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 MeIQx inhibits the activity of SLC22A3 [27]

Drug in Phase 1 Trial

  Quercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quercetin inhibits the expression of SLC22A3 [23]

  Sodium arsenite

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sodium arsenite inhibits the expression of SLC22A3 [30]

Drug in Preclinical Test

  Beta-carboline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Beta-carboline inhibits the activity of SLC22A3 [27]

Discontinued Drug

  Dizocilpine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 224 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

  Antiparasitics

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 20.4 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

Investigative Drug

  Tetraethylammonium

            3 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 1372 microM) [5]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human retinal pigment epithelial (HRPE) cells-OCT3

  DT Modulation 2

 Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1237 microM) [1]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Oocytes-OCT3

  DT Modulation 3

 Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1476.6 microM) [3]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Phencyclidine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 333 microM) [10]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

Drug Withdrawn

  Etilefrine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 4448 microM) [2]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Chinese hamster ovary (CHO) cells-OCT3

  Phenformin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phenformin inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 134 microM) [6]

Affected Drug/Substrate

 N-methylpyridinium Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCT3

Natural Product

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC22A3 [29]

  Particulate Matter

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Particulate Matter inhibits the expression of SLC22A3 [34]

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin inhibits the expression of SLC22A3 [32]

Mycotoxins

  Aflatoxin B1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aflatoxin B1 inhibits the expression of SLC22A3 [33]

Acute Toxic Substance

  Oxyquinoline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Oxyquinoline inhibits the expression of SLC22A3 [23]

  Formaldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Formaldehyde increases the expression of SLC22A3 [24]

  2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the activity of SLC22A3 [27]

Carcinogen

  2-amino-3-methylimidazo(4,5-f)quinoline

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 2-amino-3-methylimidazo(4,5-f)quinoline inhibits the activity of SLC22A3 [27]

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC22A3 [31]

Health and Environmental Toxicant

  Butyraldehyde

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Butyraldehyde inhibits the expression of SLC22A3 [25]

  tris(1,3-dichloro-2-propyl)phosphate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 tris(1,3-dichloro-2-propyl)phosphate inhibits the expression of SLC22A3 [26]

Chemical Compound

  Pentanal

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pentanal inhibits the expression of SLC22A3 [25]
References
1 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
2 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
3 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
4 A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). Bioorg Med Chem Lett. 2017 Sep 15;27(18):4440-4445.
5 Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
6 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
7 Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res. 2008 Jul;42(8):605-11.
8 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
9 Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10.
10 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
11 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
12 Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
13 Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75.
14 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
15 Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. J Pharm Sci. 2012 Jan;101(1):394-404.
16 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
17 Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003.
18 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
19 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20.
20 LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
21 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
22 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
23 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
24 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
25 Integrated analysis of microRNA and mRNA expression profiles highlights aldehyde-induced inflammatory responses in cells relevant for lung toxicity. Toxicology. 2015 Aug 6;334:111-21.
26 Defensive and adverse energy-related molecular responses precede tris (1, 3-dichloro-2-propyl) phosphate cytotoxicity. J Appl Toxicol. 2016 May;36(5):649-58.
27 Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Toxicol In Vitro. 2019 Feb;54:10-22.
28 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
29 Assessment of a 72-hour repeated exposure to Swedish snus extract and total particulate matter from 3R4F cigarette smoke on gingival organotypic cultures. Food Chem Toxicol. 2019 Mar;125:252-270.
30 Dynamic alteration in miRNA and mRNA expression profiles at different stages of chronic arsenic exposure-induced carcinogenesis in a human cell culture model of skin cancer. Arch Toxicol. 2021 Jul;95(7):2351-2365.
31 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297.
32 Two persistent organic pollutants which act through different xenosensors (alpha-endosulfan and 2,3,7,8 tetrachlorodibenzo-p-dioxin) interact in a mixture and downregulate multiple genes involved in human hepatocyte lipid and glucose metabolism. Biochimie. 2015 Sep;116:79-91.
33 Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):176-87.
34 Transcriptional profiling of human bronchial epithelial cell BEAS-2B exposed to diesel and biomass ultrafine particles. BMC Genomics. 2018 Apr 27;19(1):302.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.